☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Samsung Bioepis
Samsung Bioepis Successfully Resolves Patent Disputes with Johnson & Johnson
December 1, 2023
The US FDA Accepted to Review Samsung Bioepis & Organon’s sBLA for Hadlima (Biosimilar, adalimumab) to Treat Plaque Psoriasis
November 9, 2023
Samsung Bioepis Presents Post-hoc Analysis of P-III Clinical Trial for SB15, a Proposed Biosimilar to Eylea (Aflibercept) at EURET...
October 9, 2023
Insights+ Key Biosimilars Events of August 2023
September 7, 2023
Samsung Bioepis and Organon Report Interchangeability Study Results of SB5 (biosimilar, adalimumab) for Chronic Plaque Psoriasis
August 2, 2023
Samsung Bioepis Reports P-III Equivalence Study Results of SB11 (biosimilar, ranibizumab) for Neovascular Age-Related Macular Dege...
July 4, 2023
Load more...
Back to Home